Prof. Capdevila shares his views on the potential impact of ongoing phase III studies on the guidelines for managing well-differentiated neuroendocrine tumors.

Professor Nagarajah guides us through the latest developments in PSMA-targeting radiopharmaceuticals and shares his views on the role of dosimetry in radionuclide therapy.

Prof. Grana provides an overview of the main issues and challenges currently facing PRRT and its role in managing NETs.